| Overall cohort (n = 1211; 100%) | CTO status | |||
---|---|---|---|---|---|
pre = no/post = no (n = 689; 57%) | pre = yes/post = yes (n = 275; 23%) | pre = yes/post = no (n = 133; 11%) | pre = no/post = yes (n = 114; 9%) | ||
Age, years | |||||
 Mean (SD) | 38 (14) | 39 (14) | 38 (14) | 38 (12) | 34 (14) |
Categories, n (%) | |||||
 18–24 | 239 (19.7%) | 134 (19.5%) | 44 (16.0%) | 24 (18.1%) | 37 (32.5%) |
 25–29 | 196 (16.2%) | 101 (14.7%) | 58 (21.1%) | 18 (13.5%) | 19 (16.7%) |
 30–34 | 150 (12.4%) | 95 (13.8%) | 27 (9.8%) | 14 (10.5%) | 14 (12.3%) |
 35–39 | 132 (10.9%) | 64 (9.3%) | 43 (15.6%) | 15 (11.3%) | 10 (8.8%) |
 40–44 | 124 (10.2%) | 64 (9.3%) | 26 (9.5%) | 24 (18.1%) | 10 (8.8%) |
 45–49 | 105 (8.7%) | 66 (9.6%) | 17 (6.2%) | 15 (11.3%) |  < 10 (< 8.8%) |
 50–54 | 101 (8.3%) | 63 (9.1%) | 22 (8.0%) | 12 (9.0%) |  < 10 (< 8.8%) |
 55–59 | 69 (5.7%) | 43 (6.2%) | 15 (5.5%) |  < 10 (< 7.5%) |  < 10 (< 8.8%) |
 60–64 | 40 (3.3%) | 25 (3.6%) |  < 15 (< 5.5%) |  < 10 (< 7.5%) |  < 10 (< 8.8%) |
  ≥ 65 | 55 (4.5%) | 34 (4.9%) |  < 15 (< 5.5%) |  < 10 (< 7.5%) |  < 10 (< 8.8%) |
Sex, n (%) | |||||
 Male | 779 (64.3%) | 436 (63.3%) | 177 (64.4%) | 84 (63.2%) | 82 (71.9%) |
 Female | 432 (35.7%) | 253 (36.7%) | 98 (35.6%) | 49 (36.8%) | 32 (28.1%) |
Residence, n (%) | |||||
 Urban | 1078 (89.0%) | 608 (88.2%) | 252 (91.6%) | 118 (88.7%) | 100 (87.7%) |
 Rural | 133 (11.0%) | 81 (11.8%) | 23 (8.4%) | 15 (11.3%) | 14 (12.3%) |
CCI, mean (SD) | 0.6 (1.3) | 0.7 (1.4) | 0.5 (1.0) | 0.6 (1.3) | 0.6 (1.0) |
Hospitalized on index date, n (%) | 161 (13.3%) | 87 (12.6%) | 36 (13.1%) |  < 10 (< 7.5%) | 31 (27.2%) |
Index SGA-LAI, n (%) | |||||
 Paliperidone | 833 (68.8%) | 471 (68.4%) | 186 (67.6%) | 95 (71.4%) | 81 (71.1%) |
 Aripiprazole | 229 (18.8%) | 126 (18.3%) | 58 (21.1%) | 26 (19.5%) | 19 (16.7%) |
 Risperidone | 149 (12.3%) | 92 (13.4%) | 31 (11.3%) | 14 (11.3%) | 14 (12.3%) |